Daly Richard J's Form 4 filing
Catalyst Pharmaceuticals, Inc. (CPRX) · filed Aug 28, 2025
- Accession no.
- 0001161697-25-000300
- Filed
- Aug 28, 2025
- Trade date
- Aug 26, 2025
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $473.6K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Daly Richard JCIK 0001635393 | Director, Officer (President and CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 26, 2025 | Common stock, par value $0.001 per share | MOption exerciseAcquired | +50,000 | $2.24 | +$112,000 | 249,764 | Direct | |
| Aug 26, 2025 | Common stock, par value $0.001 per share | SSaleDisposed | −22,970 | $20.62F1 | −$473,641.4 | 226,794 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 26, 2025 | Common Stock | MOption exerciseDisposed | −50,000 | $0.00 | $0 | 2,184,753 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Shares were sold on the open market to fund the exercise price and tax withholding due from Mr. Daly on the exercise of the 50,000 stock options reported on Table II.
Referenced by the price of 1 transaction in Table I.